Header Logo

Connection

ROBERT ATMAR to Viral Vaccines

Back to Details
This is a "connection" page, showing publications ROBERT ATMAR has written about Viral Vaccines.
ROBERT ATMAR
Connection Strength
6.183
Viral Vaccines
  1. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
    View in: PubMed
    Score: 0.679
  2. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 02 18; 221(5):739-743.
    View in: PubMed
    Score: 0.506
  3. Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination. J Infect Dis. 2019 07 19; 220(4):603-614.
    View in: PubMed
    Score: 0.486
  4. An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults. J Infect Dis. 2019 01 09; 219(3):410-414.
    View in: PubMed
    Score: 0.469
  5. Prospects and Challenges in the Development of a Norovirus Vaccine. Clin Ther. 2017 Aug; 39(8):1537-1549.
    View in: PubMed
    Score: 0.424
  6. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine. Clin Vaccine Immunol. 2017 May; 24(5).
    View in: PubMed
    Score: 0.417
  7. Correlates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go? PLoS Pathog. 2016 04; 12(4):e1005334.
    View in: PubMed
    Score: 0.389
  8. Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection. Clin Vaccine Immunol. 2016 02; 23(2):181-3.
    View in: PubMed
    Score: 0.379
  9. Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug; 22(8):923-9.
    View in: PubMed
    Score: 0.365
  10. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 08; 365(23):2178-87.
    View in: PubMed
    Score: 0.287
  11. Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses. J Infect Dis. 2021 10 28; 224(8):1372-1382.
    View in: PubMed
    Score: 0.285
  12. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
    View in: PubMed
    Score: 0.209
  13. Norovirus replication, host interactions and vaccine advances. Nat Rev Microbiol. 2025 Jun; 23(6):385-401.
    View in: PubMed
    Score: 0.178
  14. Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
    View in: PubMed
    Score: 0.177
  15. The Promise of New Vaccines Against Respiratory Viruses. Pediatrics. 2024 06 01; 153(6).
    View in: PubMed
    Score: 0.170
  16. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 07 19; 3(7):100679.
    View in: PubMed
    Score: 0.149
  17. Human noroviruses: recent advances in a 50-year history. Curr Opin Infect Dis. 2018 10; 31(5):422-432.
    View in: PubMed
    Score: 0.115
  18. Antiviral targets of human noroviruses. Curr Opin Virol. 2016 06; 18:117-25.
    View in: PubMed
    Score: 0.098
  19. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine. 2015 Jan 15; 33(4):568-76.
    View in: PubMed
    Score: 0.088
  20. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014 Dec 01; 210(11):1763-71.
    View in: PubMed
    Score: 0.085
  21. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012; 7(4):e35421.
    View in: PubMed
    Score: 0.074
  22. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med. 1991 Jan 15; 114(2):119-27.
    View in: PubMed
    Score: 0.067
  23. Infections in Hispanic immigrants. Clin Infect Dis. 2002 Jun 15; 34(12):1627-32.
    View in: PubMed
    Score: 0.037
  24. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol. 1998 Feb; 72(2):1345-53.
    View in: PubMed
    Score: 0.027
  25. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015 Mar 15; 211(6):870-8.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.